BCRX - BioCryst Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real-time price. Currency in USD
5.94
-0.12 (-1.98%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous close6.06
Open6.05
Bid5.91 x 3300
Ask6.21 x 100
Day's range5.94 - 6.11
52-week range3.95 - 6.67
Volume275,016
Avg. volume792,950
Market cap586.378M
Beta2.21
PE ratio (TTM)N/A
EPS (TTM)-0.86
Earnings date6 Aug 2018 - 10 Aug 2018
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est8.33
Trade prices are not sourced from all markets
  • Why American Airlines, Idera Pharmaceuticals, and RH Holdings Slumped Today
    Motley Fool11 days ago

    Why American Airlines, Idera Pharmaceuticals, and RH Holdings Slumped Today

    From a scuttled merger to tariff troubles, see why shares of these three companies fell hard today.

  • Why Idera Pharmaceuticals Is Sinking Today
    Motley Fool11 days ago

    Why Idera Pharmaceuticals Is Sinking Today

    Shares plunge after its proposed merger is called off. Here's what investors need to know.

  • The Wall Street Journal12 days ago

    Stocks to Watch: Boeing, Ford, American Airlines, JetBlue, Pfizer, Comcast, Alphabet, Nvidia, AbbVie

    Among the companies with shares expected to trade actively in Wednesday's session are Boeing, Ford, American Airlines, Pfizer and Comcast.

  • Business Wire12 days ago

    BioCryst Provides Update on Strategy, Pipeline and Outlook

    BioCryst Pharmaceuticals, Inc. (BCRX) (“BioCryst” or the “Company”), a pharmaceutical company focused on the development and commercialization of treatments for rare diseases, today provided an update on the Company’s strategic and financial outlook as a standalone company following the recent termination of its merger agreement with Idera Pharmaceuticals, Inc. (IDRA) (“Idera”). Jon P. Stonehouse, President and Chief Executive Officer of BioCryst, said, “We are moving forward executing our standalone strategy with a great deal of confidence in our programs, our pipeline and our ability to drive value for our stockholders. Also, we are on track for a first half of 2019 initiation of a Phase 1 clinical trial for our ALK-2 inhibitor program for treating fibrodysplasia ossificans progressiva, or FOP.

  • The Wall Street Journal12 days ago

    [$$] Idera Pharmaceuticals and BioCryst Pharmaceuticals Terminate Merger Plans

    Inc. called off merger plans Tuesday after BioCryst shareholders voted against the proposal, triggering a $6 million penalty to be paid to Idera. Some BioCryst shareholders, including Great Point Partners LLC and RA Capital Management LLC, had publicly objected to the merger plan and noted that they intended to vote against it.

  • MarketWatch12 days ago

    BioCryst's stock jumps, Idera drops as proposed merger called off

    MARKET PULSE Shares of BioCryst Pharmaceuticals Inc. (bcrx) and Idera Pharmaceuticals Inc. (idra) were active in the extended session Tuesday following a brief halt after BioCryst shareholders voted down a merger between the two drug companies.

  • Business Wire12 days ago

    BioCryst Pharmaceuticals Announces Termination of Merger Agreement with Idera Pharmaceuticals

    BioCryst Pharmaceuticals, Inc. (BCRX) (“BioCryst”) today announced that it has terminated the previously announced merger agreement with Idera Pharmaceuticals, Inc. (IDRA) (“Idera”) following the BioCryst stockholders’ failure to approve the adoption of the merger agreement at the BioCryst Special Meeting of Stockholders held today. “We respect and understand the views of our stockholders and are moving forward fully-focused on executing our business plan as a standalone company,” said Jon P. Stonehouse, BioCryst’s President and Chief Executive Officer.

  • Idera Stock Down, Study on Dermatomyositis Candidate Fails
    Zackslast month

    Idera Stock Down, Study on Dermatomyositis Candidate Fails

    Shares of Idera (IDRA) decline following the failure of a phase II study of its pipeline candidate, IMO-8400, on adult patients with dermatomyositis.

  • Business Wire2 months ago

    BioCryst Issues Letter to Stockholders Reiterating Upside Potential of Value-Enhancing Merger with Idera

    BioCryst Pharmaceuticals, Inc. (BCRX) (“BioCryst” or the “Company”), a pharmaceutical company focused on the development and commercialization of treatments for rare diseases, today issued an open letter to stockholders in connection with the Company’s Special Meeting of Stockholders to be held on July 10, 2018. BioCryst’s Special Meeting of Stockholders is scheduled for July 10, 2018. The BioCryst Board of Directors believes this transaction represents a significant opportunity to enhance the value of your investment in BioCryst and unanimously recommends that stockholders vote “FOR” the transaction, which will create a new company to be called Valenscion Incorporated (“Valenscion” or the “combined company”).

  • Associated Press2 months ago

    BioCryst: 1Q Earnings Snapshot

    On a per-share basis, the Durham, North Carolina-based company said it had a loss of 26 cents. The results fell short of Wall Street expectations. The average estimate of four analysts surveyed by Zacks ...

  • Business Wire3 months ago

    BioCryst Pharmaceuticals and Idera Pharmaceuticals Reschedule Meetings to Vote on Proposed Merger

    BioCryst Pharmaceuticals, Inc. and Idera Pharmaceuticals, Inc. today jointly announced that they have each rescheduled their respective Special Meetings of Stockholders to vote on the proposed merger of BioCryst and Idera to July 10, 2018 at 10:00 AM ET.

  • Business Wire4 months ago

    BioCryst Pharmaceuticals Files Definitive Proxy Statement in Connection with Pending Merger with Idera Pharmaceuticals

    BioCryst Pharmaceuticals, Inc. today announced that it has filed definitive proxy materials with the U.S. Securities and Exchange Commission in connection with the pending merger of BioCryst and Idera.

  • Associated Press5 months ago

    BioCryst reports 4Q loss

    The Durham, North Carolina-based company said it had a loss of 20 cents per share. The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...

  • Options Traders Expect Huge Moves in BioCryst (BCRX) Stock
    Zacks5 months ago

    Options Traders Expect Huge Moves in BioCryst (BCRX) Stock

    Investors in BioCryst (BCRX) need to pay close attention to the stock based on moves in the options market lately.

  • Is the Options Market Predicting a Spike in BioCryst (BCRX) Stock?
    Zacks6 months ago

    Is the Options Market Predicting a Spike in BioCryst (BCRX) Stock?

    Investors need to pay close attention to BioCryst (BCRX) stock based on the movements in the options market lately.

  • BioCryst (BCRX) & Idera (IDRA) Announce Merger, Shares Fall
    Zacks6 months ago

    BioCryst (BCRX) & Idera (IDRA) Announce Merger, Shares Fall

    Shares of BioCryst Pharmaceuticals (BCRX) and Idera Pharmaceuticals (IDRA) plunge following the announcement of their merger.

  • BioCryst Pharmaceuticals' and Idera Pharmaceuticals' Merger Announcement Gets No Love
    Motley Fool6 months ago

    BioCryst Pharmaceuticals' and Idera Pharmaceuticals' Merger Announcement Gets No Love

    Is this a merger out of weakness and necessity? Wall Street might think so.

  • Here's Why BioCryst Pharmaceuticals Gained as Much as 15.7% Today
    Motley Fool7 months ago

    Here's Why BioCryst Pharmaceuticals Gained as Much as 15.7% Today

    An analyst upgraded the stock to start off the new year.

  • Associated Press8 months ago

    BioCryst reports 3Q loss

    On a per-share basis, the Durham, North Carolina-based company said it had a loss of 18 cents. The results fell short of Wall Street expectations. The average estimate of six analysts surveyed by Zacks ...

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes